Loading
An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.
ISB 2001 is a trispecific antibody from Ichnos Glenmark Innovation that binds BCMA and CD38 on multiple myeloma cells and CD3 on T cells, with the aim of engaging tumours that express either antigen at low levels and reducing escape through single-antigen loss. It has been in phase 1 for relapsed or refractory multiple myeloma with orphan drug designation in the US. In July 2025 AbbVie licensed it for North America, Europe, Japan and Greater China for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties, with Glenmark retaining India and emerging markets. It is the clearest sign that Indian discovery, not only manufacturing, is entering global oncology.
1.One arm of ISB 2001 binds BCMA on the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ISB 2001" OR ABSTRACT:"ISB 2001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ISB 2001, not a curated reading list.
Shares Talquetamab, Teclistamab, T-cell engagers (bispecific), Multiple myeloma.
Shares Teclistamab, CD38, BCMA, Bispecific antibodies.
Shares Talquetamab, Teclistamab, BCMA, Multiple myeloma.
Shares Talquetamab, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Teclistamab, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Teclistamab, BCMA, Bispecific antibodies.
Shares Talquetamab, Teclistamab, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Teclistamab, T-cell engagers (bispecific), Multiple myeloma.